Ads
related to: chemotherapy prostate cancer life expectancy- Patient Resources
Download informative brochures for
patients and caregivers.
- Find An Imaging Site
Locate the nearest imaging site
or contact customer service.
- Talk To Your Doctor
Review questions to start a
conversation with your doctor.
- Reimbursement Support
The patient support program
can assist insurance assessment.
- Patient Resources
Search results
Results from the WOW.Com Content Network
The National Institute of Health (NIH) attributes the increase in the 5-year relative survival of prostate cancer (from 69% in the 1970s to 100% in 2006) to screening and diagnosis and due to the fact that men that participate in screening tend to be healthier and live longer than the average man and testing techniques that are able to detect ...
It is not clear if cryosurgery improves the quality of life and mortality from prostate cancer compared to radiation therapy. [15] Potential adverse effects associated with cryosurgery include urinary retention, incontinence, and pain in the perineal region, penis, or scrotum. [15] Impotence occurs up to ninety percent of the time.
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
The Prostate Cancer Intervention versus Observation Trial (PIVOT) randomized 731 men diagnosed with localized prostate cancer to radical prostatectomy or observation (mean age 67 years; median PSA 7.8 ng/ml). [10] In the observation group, bone metastases and prostate cancer death occurred in 10.6% and 8.4%, respectively through 12 years. [10]
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
Ads
related to: chemotherapy prostate cancer life expectancy